Three more Phase 3 clinical trials of ABT-494 will begin enrollment in early 2016 and will include patients with an inadequate response to biologics and patients who are MTX-naive

Source Link:

http://abbvie.mediaroom.com/2016-01-08-AbbVie-Announces-the-Launch-of-Robust-Phase-3-Clinical-Trial-Program-Evaluating-ABT-494-an-Investigational-Selective-JAK1-Inhibitor-for-the-Treatment-of-Rheumatoid-Arthritis